SmithKline riding high

Article Abstract:

SmithKline Beecham has benefited from a rise in sales for Paroxetine, an anti-depressant. Four brokers from a sample of six rate the company's stocks a buy, one rates them a hold, and one rates them a sell. The buyers are Sutherlands, Dresdner Kleinwort Benson, Salomon Brothers and Merrill Lynch. The holder is BZW, which notes that the strength of pound sterling is harming the company's sales, and the seller is Greig Middleton, which sees the stock price as having risen too far.

SmithKline Beecham PLC

---

Glaxo has four fans

Article Abstract:

Glaxo Wellcome is threatened by the loss of patent protection for its Zantac product, and the impact this has will depend partlyon the company's ability to develop new drugs to sell. The company's stock price has risen, despite this concern, and four brokers rate the company's stocks a buy. The buyers are Williams de Broe, Grieg Middleton, Societe Generale and Charles Stanley. Merrill Lynch expresses greater caution and Yamaichi is more cautious still.

Glaxo Wellcome PLC

---

Oxford GlycoSciences

Article Abstract:

UK drug discovery and development firm Oxford GlycoSciences' GBP196 mil cash pile and its strong platform technology make its shares look a good buy. The firm expects to launch its Vevesca drug soon, to treat Gaucher's disease.

Biotechnology industry, Biotechnology industries, Oxford GlycoSciences PLC

Similar abstracts:

• Abstracts: Building up margins. Ready for expansion. White Young Green
• Abstracts: Splitting the difference. Cyclical value funds. Funds of funds fallacy
• Abstracts: SmithKline shoots up. Withdrawal symptoms. Sanofi-Synthelabo
• Abstracts: A big pill to swallow. Glaxo will surge by '99. Pharmagene
• Abstracts: The road to empowerment. Trusting your instincts. Sites for sore eyes

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.